GNFT Quote, Financials, Valuation and Earnings

Biodexa Pharmaceuticals PLC has a net margin of -- compared to Genfit SA's net margin of --. Genfit SA's return on equity of -- beat Biodexa Pharmaceuticals PLC's return on equity of -160.77%.

Genfit SA has a consensus price target of $8.70, signalling upside risk potential of 126.92%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of $17.94 which suggests that it could grow by 2041.28%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Genfit SA, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Genfit SA.

Genfit SA has a beta of 1.082, which suggesting that the stock is 8.244% more volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.167, suggesting its more volatile than the S&P 500 by 16.654%.

Genfit SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genfit SA pays -- of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend.

Genfit SA quarterly revenues are --, which are smaller than Biodexa Pharmaceuticals PLC quarterly revenues of --. Genfit SA's net income of -- is lower than Biodexa Pharmaceuticals PLC's net income of --. Notably, Genfit SA's price-to-earnings ratio is 32.57x while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genfit SA is 2.66x versus 0.87x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.

Cellectis SA has a net margin of -- compared to Genfit SA's net margin of -170.14%. Genfit SA's return on equity of -- beat Cellectis SA's return on equity of -49.15%.

Genfit SA has a consensus price target of $8.70, signalling upside risk potential of 126.92%. On the other hand Cellectis SA has an analysts' consensus of $5.75 which suggests that it could grow by 188.95%. Given that Cellectis SA has higher upside potential than Genfit SA, analysts believe Cellectis SA is more attractive than Genfit SA.

Genfit SA has a beta of 1.082, which suggesting that the stock is 8.244% more volatile than S&P 500. In comparison Cellectis SA has a beta of 2.910, suggesting its more volatile than the S&P 500 by 191%.

Genfit SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cellectis SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genfit SA pays -- of its earnings as a dividend. Cellectis SA pays out -- of its earnings as a dividend.

Genfit SA quarterly revenues are --, which are smaller than Cellectis SA quarterly revenues of $10.7M. Genfit SA's net income of -- is lower than Cellectis SA's net income of -$18.1M. Notably, Genfit SA's price-to-earnings ratio is 32.57x while Cellectis SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genfit SA is 2.66x versus 4.08x for Cellectis SA. Usually stocks with elevated PS ratios are considered overvalued.

DBV Technologies SA has a net margin of -- compared to Genfit SA's net margin of --. Genfit SA's return on equity of -- beat DBV Technologies SA's return on equity of --.

Genfit SA has a consensus price target of $8.70, signalling upside risk potential of 126.92%. On the other hand DBV Technologies SA has an analysts' consensus of $16.06 which suggests that it could grow by 64.81%. Given that Genfit SA has higher upside potential than DBV Technologies SA, analysts believe Genfit SA is more attractive than DBV Technologies SA.

Genfit SA has a beta of 1.082, which suggesting that the stock is 8.244% more volatile than S&P 500. In comparison DBV Technologies SA has a beta of -0.587, suggesting its less volatile than the S&P 500 by 158.693%.

Genfit SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genfit SA pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

Genfit SA quarterly revenues are --, which are smaller than DBV Technologies SA quarterly revenues of --. Genfit SA's net income of -- is lower than DBV Technologies SA's net income of -$27.1M. Notably, Genfit SA's price-to-earnings ratio is 32.57x while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genfit SA is 2.66x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

Edap TMS SA has a net margin of -- compared to Genfit SA's net margin of -52.18%. Genfit SA's return on equity of -- beat Edap TMS SA's return on equity of -49.1%.

Genfit SA has a consensus price target of $8.70, signalling upside risk potential of 126.92%. On the other hand Edap TMS SA has an analysts' consensus of $5.75 which suggests that it could grow by 291.16%. Given that Edap TMS SA has higher upside potential than Genfit SA, analysts believe Edap TMS SA is more attractive than Genfit SA.

Genfit SA has a beta of 1.082, which suggesting that the stock is 8.244% more volatile than S&P 500. In comparison Edap TMS SA has a beta of -0.003, suggesting its less volatile than the S&P 500 by 100.255%.

Genfit SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edap TMS SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genfit SA pays -- of its earnings as a dividend. Edap TMS SA pays out -- of its earnings as a dividend.

Genfit SA quarterly revenues are --, which are smaller than Edap TMS SA quarterly revenues of $14.3M. Genfit SA's net income of -- is lower than Edap TMS SA's net income of -$7.4M. Notably, Genfit SA's price-to-earnings ratio is 32.57x while Edap TMS SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genfit SA is 2.66x versus 0.82x for Edap TMS SA. Usually stocks with elevated PS ratios are considered overvalued.